Athersys logo
Athersys ATHX

Quarterly report 2023-Q3
added 11-16-2023

report update icon

Athersys Financial Ratios 2011-2026 | ATHX

Annual Financial Ratios Athersys

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

- -4.6 -4.7 -8.8 -6.2 -6.3 -5.8 -7.3 -7.3 -3.1 -3.1

P/S

- 252.6 37.4 8.8 54.1 5.6 8.0 99.1 91.8 5.2 4.2

EPS

-0.4 -0.4 -0.3 -0.2 -0.3 -0.2 -0.2 -0.3 -0.5 -0.5 -0.6

EV (Enterprise Value)

-37.4 M 341 M 194 M 182 M 181 M 89.7 M 77.7 M 143 M 206 M 27.4 M 42.8 M

EBITDA per Share

-0.382 -0.413 -0.295 -0.182 -0.291 -0.181 -0.206 -0.372 -0.418 -0.482 -0.581

EV/EBITDA

0.4 -4.0 -3.9 -6.6 -5.3 -5.4 -4.3 -4.7 -8.0 -1.3 -2.6

PEG

- 0.06 0.08 -0.23 0.1 -0.63 -0.19 -0.16 0.41 -0.13 -1.89

P/B

- 11.6 9.1 5.0 8.6 8.6 4.8 7.7 11.3 2.3 5.9

P/CF

- -5.8 -5.9 -14.4 -8.3 -7.6 -6.9 -6.2 -9.7 -2.5 -2.9

ROE %

-531.22 -251.15 -191.58 -56.32 -137.92 -137.17 -83.26 -105.68 -155.10 -72.78 -188.35

ROA %

-144.48 -131.90 -107.00 -39.34 -95.98 -80.47 -65.35 -76.89 -89.92 -53.38 -87.55

ROCE %

-531.85 -213.09 -157.79 -55.48 -141.57 -128.91 -84.28 -120.75 -82.02 -69.19 -166.41

Current Ratio

- 2.4 2.9 3.7 3.1 2.4 5.0 5.8 7.5 5.9 1.9

DSO

- 22.6 62.3 75.0 72.7 12.6 11.0 156.1 77.9 20.5 24.3

All numbers in USD currency

Quarterly Financial Ratios Athersys

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.15 -0.62 -0.43 - -1.15 -2.28 -2.27 -0.09 -1.76 -0.1 -0.13 -0.11 -0.11 -0.1 -0.1 -0.06 -0.08 -0.06 -0.09 -0.08 -0.07 0.05 -0.08 -0.11 -0.06 -0.06 -0.06 -0.08 -0.07 -0.08 0.06 0.04 -0.08 0.01 -0.16 -0.08 -0.06 0.01 -0.15 -0.15 -0.1 -0.11 -0.18 -0.07 -0.12 -0.13 -0.17 -0.18 -0.1 -0.14 -0.18

EBITDA per Share

-278 -0.63 -0.4 - -1.36 K -2.28 -2.27 -2.23 -1.75 -0.1 -0.13 -0.11 -0.11 -0.09 -0.1 -0.06 -0.08 -0.06 -0.09 -0.08 -0.07 0.05 -0.08 -0.11 -0.06 -0.06 -0.06 - -0.07 -0.09 0.08 - -0.08 -0.08 -0.09 - -0.09 -0.09 -0.1 - -0.1 -0.11 -0.13 - -0.14 -0.12 -0.16 - -0.13 -0.14 -0.12

ROE %

152.37 224.29 391.24 -6952.72 -7085.35 -7222.76 -7582.29 -414.23 -352.40 -369.16 -269.69 -251.15 -222.98 -202.73 -185.79 -191.58 -175.19 -146.15 -88.44 -56.32 -86.10 -94.50 -137.39 -137.92 -145.63 -168.34 -203.74 -137.17 -55.22 -34.46 22.51 -85.62 -135.20 -124.84 -116.36 -105.68 -123.73 -129.47 -162.70 -155.10 -121.67 -110.38 -98.72 -72.78 -115.05 -130.09 -155.92 -188.35 -32.08 -44.16 -53.85

ROA %

-248.69 -236.38 -180.20 -155.05 -191.12 -175.10 -174.87 -162.06 -163.17 -178.48 -142.31 -131.90 -118.53 -109.62 -102.10 -107.00 -101.52 -88.46 -53.98 -39.34 -59.99 -65.78 -95.66 -95.98 -94.37 -104.31 -122.15 -80.47 -28.78 -23.13 9.24 -65.35 -102.47 -93.04 -86.58 -76.89 -82.72 -82.71 -102.45 -89.92 -73.00 -69.07 -65.13 -53.38 -68.74 -71.15 -78.23 -87.55 -14.91 -20.53 -25.03

ROCE %

180.34 259.58 431.55 -6981.96 -7114.38 -7270.26 -7549.65 -329.14 -266.61 -282.49 -268.26 -249.77 -222.79 -204.66 -188.74 -195.47 -179.36 -149.46 -91.27 -58.09 -87.83 -96.05 -138.81 -142.38 -141.43 -165.64 -203.64 -60.67 -94.63 -73.03 -43.57 -105.88 -140.66 -141.48 -140.69 -105.02 -133.29 -126.78 -123.07 -93.96 -114.95 -107.66 -94.34 -59.36 -102.64 -124.94 -154.62 -130.23 -43.29 -47.52 -39.42

DSO

- - - - 421.1 11.8 - - - - - - - - - - - - 8.3 25.2 22.0 3.1 57.6 45.7 134.0 79.9 36.8 55.5 182.8 95.5 2.8 3.1 316.0 579.4 65.8 263.9 214.9 189.2 91.2 51.6 76.4 83.1 141.3 19.5 44.0 16.8 19.6 24.5 26.7 25.8 -

Operating Cycle

- - - - 421.1 11.8 - - - - - - - - - - - - 8.3 25.2 22.0 3.1 57.6 45.7 134.0 79.9 36.8 55.5 182.8 95.5 2.8 3.1 316.0 579.4 65.8 263.9 214.9 189.2 91.2 51.6 76.4 83.1 141.3 19.5 44.0 16.8 19.6 24.5 26.7 25.8 -

Cash Conversion Cycle

- - - - 421.1 11.8 - - - - - - - - - - - - 8.3 25.2 22.0 3.1 57.6 45.7 134.0 79.9 36.8 55.5 182.8 95.5 2.8 3.1 316.0 579.4 65.8 263.9 214.9 189.2 91.2 51.6 76.4 83.1 141.3 19.5 44.0 16.8 19.6 24.5 26.7 25.8 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Athersys, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Verastem Verastem
VSTM
$ 5.04 -4.73 % $ 349 M usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
$ 0.57 -5.87 % $ 17.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 12.41 -11.1 % $ 1.88 B usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
$ 54.48 -1.89 % $ 4.24 B canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Summit Therapeutics Summit Therapeutics
SMMT
$ 16.58 -3.94 % $ 12.4 B britainBritain
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 317.36 -3.29 % $ 41.6 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.29 -3.6 % $ 822 M canadaCanada
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
- - $ 1.41 B canadaCanada
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.01 -2.66 % $ 889 M usaUSA
Gritstone Oncology Gritstone Oncology
GRTS
- 0.42 % $ 213 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 20.75 -3.35 % $ 3.44 B usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 6.66 -5.4 % $ 65.8 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Alkermes plc Alkermes plc
ALKS
$ 29.39 -1.77 % $ 4.84 B irlandaIrlanda
Cabaletta Bio Cabaletta Bio
CABA
$ 2.68 -4.96 % $ 269 M usaUSA
AbbVie AbbVie
ABBV
$ 209.4 -0.81 % $ 370 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.27 -2.39 % $ 977 M canadaCanada
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA